Courtney D. DiNardo, MD, MSCE, on the Approval of a Venetoclax Combo in Older Adults with AML
October 30, 2020

Venetoclax was granted approval in combination with azacitidine, decitabine, or low dose cytarabine earlier this month for adults 75 years or older with newly diagnosed acute myeloid leukemia or those who have comorbidities precluding intensive induction chemotherapy.

ASTRO Releases New Clinical Guidelines for Use of Radiation Therapy in Locally Advanced Rectal Cancer
October 30, 2020

The updated guidelines outlined indications and best practices for pelvic radiation treatments, as well as the integration of radiation with chemotherapy and surgery for patients with stage II to III disease.

Impact of COVID-19 on Cancer Care May Lead to Increase in Cancer Morbidity and Mortality
October 30, 2020

This study found that the impact of COVID-19 on cancer care in the US has led to decreases and delays in identifying new cancers, as well as the delivery of treatment.

FDA Approves First Companion Diagnostic for Expanded EGFR TKI Therapies in NSCLC
October 30, 2020

The FDA approved expanded claims for the cobas EGFR Mutation Test v2 as a companion diagnostic for a broader group of therapies in the treatment of non-small cell lung cancer.

Beat AML Master Clinical Trial Shows Promise for Precision Medicine in the Treatment of AML
October 29, 2020

Patients who participated in the Beat AML Master clinical trial were found to have superior outcomes with precision medicine, compared to patients with acute myeloid leukemia who opted for standard chemotherapy treatment.

Beneficial, Cost-Effective Breast Cancer Therapy Not Offered to All Patients
October 29, 2020

A study led by Jefferson researchers found that not all patients, specifically African American patients and women without private insurance, receive the same breast cancer treatment, specifically the beneficial and more cost-effective hypofractionated whole breast radiation therapy.